Octave Bioscience
MENLO PARK, Calif. · Biotechnology, Healthcare · 83 employees
Octave Bioscience, Inc. is a commercial growth stage precision medicine company pioneering biomarker-driven solutions for neurodegenerative diseases, with an initial focus on Multiple Sclerosis, and Parkinson’s Disease in partnership with the Michael J. Fox Foundation. Octave’s comprehensive testing solutions provide objective, actionable insights to improve disease monitoring, treatment decisions
Funding history
- Series C — $35.6M — Sep 2025
- Venture - Series Unknown — $31.8M — Mar 2025
- Venture - Series Unknown — $7.0M — Nov 2023
- Venture - Series Unknown — $32.5M — Nov 2023
- Funding Round — Undisclosed — Jul 2023
Recent signals
- Jan 08, 2026: Octave Bioscience Appoints Kirk Stockwood as Senior Vice President, Commercial
- Sep 04, 2025: Raised $35.6M in Series C
- Mar 24, 2025: Raised $31.8M in Venture - Series Unknown
- Aug 07, 2024: Octave Bioscience Appoints Marcel Konrad as Chief Financial Officer and Adds Several New Commercial Leaders
- Mar 28, 2024: Octave Bioscience Appoints Jeron Evans as Chief Revenue Officer and Debbie Ledet as Chief Access Officer
- Nov 24, 2023: Raised $7.0M in Venture - Series Unknown
- Nov 24, 2023: Raised $32.5M in Venture - Series Unknown
- Jul 26, 2023: Raised funding in Funding Round
See plans & pricing → Track Octave Bioscience’s funding, hiring, and signals — with verified contacts — on Fundz.